Core A The Administrative Core, Core A, will provide administrative, programmatic and fiscal management for the projects and cores of the Program Project. The goals are to organize staff and administer the projects and cores in conjunction with project leaders, core directors and institutional staff; organize and conduct monthly meetings of Program Project participants as well as annual meetings of Program Project participants. In addition, the aims will be to prepare the necessary documents related to Program Project activities, including reports of the Program Project investigator meetings, progress reports for official agencies and facilitate interaction between individual projects and between projects and cores. The Core Director will monitor the progress of the individual projects on a regular basis to maintain appropriate fiscal oversight of the projects and cores. The Core Directors will oversee the preparation of the necessary fiscal reports of official agencies and assure compliance with appropriate regulations regarding experimentation with human subjects including gender and minor participation and vertebrate animals.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA142106-12
Application #
9131970
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
2016-09-01
Budget End
2017-08-31
Support Year
12
Fiscal Year
2016
Total Cost
$132,070
Indirect Cost
$62,432
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Lu, Yunjie; Gao, Ji; Zhang, Shaopeng et al. (2018) miR-142-3p regulates autophagy by targeting ATG16L1 in thymic-derived regulatory T cell (tTreg). Cell Death Dis 9:290
Cichocki, Frank; Wu, Cheng-Ying; Zhang, Bin et al. (2018) ARID5B regulates metabolic programming in human adaptive NK cells. J Exp Med 215:2379-2395
Wu, Yongxia; Schutt, Steven; Paz, Katelyn et al. (2018) MicroRNA-17-92 is required for T-cell and B-cell pathogenicity in chronic graft-versus-host disease in mice. Blood 131:1974-1986
Gartlan, Kate H; Bommiasamy, Hemamalini; Paz, Katelyn et al. (2018) A critical role for donor-derived IL-22 in cutaneous chronic GVHD. Am J Transplant 18:810-820
Hippen, Keli L; Loschi, Michael; Nicholls, Jemma et al. (2018) Effects of MicroRNA on Regulatory T Cells and Implications for Adoptive Cellular Therapy to Ameliorate Graft-versus-Host Disease. Front Immunol 9:57
Koreth, John; Kim, Haesook T; Lange, Paulina B et al. (2018) Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results. Haematologica 103:522-530
Chen, Liying; Alexe, Gabriela; Dharia, Neekesh V et al. (2018) CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2. J Clin Invest 128:446-462
Kolupaev, Oleg V; Dant, Trisha A; Bommiasamy, Hemamalini et al. (2018) Impaired bone marrow B-cell development in mice with a bronchiolitis obliterans model of cGVHD. Blood Adv 2:2307-2319
Du, Jing; Flynn, Ryan; Paz, Katelyn et al. (2018) Murine chronic graft-versus-host disease proteome profiling discovers CCL15 as a novel biomarker in patients. Blood 131:1743-1754
Zeiser, Robert; Sarantopoulos, Stefanie; Blazar, Bruce R (2018) B-cell targeting in chronic graft-versus-host disease. Blood 131:1399-1405

Showing the most recent 10 out of 207 publications